Brief: Alligator Bioscience Reports Survival Benefit & Long Response Duration from Mitazalimab Phase 2 Study in First-Line Pancreatic Cancer

Alligator Bioscience AB

26/06/2024 13:18

June 26 (Reuters) - Alligator Bioscience AB  ATORX.ST :
    * ALLIGATOR BIOSCIENCE ANNOUNCES SUBSTANTIAL OVERALL
SURVIVAL
BENEFIT AND UNPRECEDENTED DURATION OF RESPONSE IN THE 18-MONTH
ANALYSIS FROM MITAZALIMAB OPTIMIZE-1 PHASE 2 STUDY IN 1ST LINE
PANCREATIC CANCER
    * MEDIAN OVERALL SURVIVAL INCREASED TO 14.9 MONTHS, SURVIVAL
RATE
AT 18 MONTHS WAS 36.2%, NEARLY TWICE AS HIGH AS 18.6% PREVIOUSLY
REPORTED FOR FOLFIRINOX
    * FURTHER DEEPENING OF TUMOR SHRINKAGE WAS EVIDENT WITH
ADDITIONAL
OBJECTIVE RESPONSES OVER LONG TREATMENT DURATION

Source text for Eikon:  ID:nMFN72QsqL 
Further company coverage:  ATORX.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com;  +48 58 769 66 00;))